Diadema Partners’s Lipocine LPCN Stock Holding History

Diadema Partners’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$400K	–	178
2026 Q1	$400K	Sell	50,000 -210,939	-81%	-$1.84M	0.07%	116
2025 Q4	$2.1M	Buy	+260,939	New	+$878K	0.36%	64

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Diadema Partners's LPCN Position: Q2 2026 in Review

Diadema Partners sold out of Lipocine (LPCN) in Q2 2026, closing a stake of 50,000 shares — an estimated $400K sold.

Diadema Partners first reported a position in LPCN in Q4 2025 and held it in 2 quarters. The position peaked at $2.1M in Q4 2025. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

Diadema Partners reported no remaining Lipocine position as of Q2 2026 after selling out during the quarter.
Diadema Partners sold 50,000 Lipocine shares in Q2 2026, an estimated $400K.
Diadema Partners first reported a position in Lipocine in Q4 2025 and held it in 2 quarters.
Diadema Partners's Lipocine position peaked at $2.1M in Q4 2025.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.